ISOQUINOLINYL AND ISOINDOLINYL DERIVATIVES AS HISTAMINE-3 ANTAGONISTS
The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor.
1 . A compound of formula I
wherein
X 1 is (CR 4 R 5 ), CO or O;
X 2a and X 2b are each H or are taken together to form ═O;
m is 0, 1 or 2;
n is 2, 3 or 4;
p is 0, 1 or 2;
q is 1, 2 or 3;
R 1 and R 2 are each independently H, halogen or an alkyl or haloalkyl group each group optionally substituted;
R 3 is NR 6 R 7 or an alkyl, cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each group optionally substituted with the proviso that when X 1 is O then R 3 must be other than NR 6 R 7 ; when X 2a and X 2b are taken together to form ═O and p is 0, then R 3 is not quinoxalinyl-2(1H)-one or an optionally substituted 1,3,4-oxadiazole; and when X 2a and X 2b are H and p is 0, then R 3 is not an optionally substituted 1,2,4-triazol-5(4H)-one;
R 4 and R 5 are each independently H or an optionally substituted alkyl or cycloalkyl group; and
R 6 and R 7 each independently H or an alkyl, alkenyl, alkoxy, cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each group optionally substituted or R 6 and R 7 may be taken together with the atom to which they are attached to form an optionally substituted 4- to 7-membered ring optionally containing one or two additional heteroatoms selected from N, O or S or an optionally substituted fused bicyclic or tricyclic 9- to 15-membered aromatic ring system optionally containing one to three additional heteroatoms selected from N, O or S; or
a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.
2 . The compound of claim 1 wherein X 1 is (CR 4 R 5 ) p or O; or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.
3 . The compound of claim 1 wherein X 1 is (CR 4 R 5 ) p and p is 0; or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.
4 . The compound of claim 1 wherein R 1 and R 2 are each independently H or methyl; or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.
5 . The compound of claim 1 wherein X 2a and X 2b are each H; or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.
6 . The compound of claim 1 wherein X 2a and X 2b are taken together to form ═O; or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.
7 . The compound of claim 1 wherein R 3 is an optionally substituted aminocarbonylphenyl or cycloheteroalkylcarbonylphenyl group; or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.
8 . The compound of claim 1 wherein R 3 is selected from the group consisting of phenyl, halophenyl, dihalophenyl, perhaloalkoxyphenyl, cyanophenyl, perhaloalkylphenyl, alkoxyphenyl, alkoxycarbonylphenyl, heteroaryl, cycloheteroalkylcarbonyl, cycloheteroalkylcarbonylphenyl, cyanoheteroaryl, carboxyphenyl, cycloalkylaminocarbonylphenyl, N,N-dialkylaminocarbonylphenyl, alkylaminocarbonylphenyl, alkycycloheteroalkylcarbonylphenyl, aminocarbonylphenyl, alkylaminocarbonylheteroaryl, cycloalkylcarbonylphenyl, cyanophenylalkoxy and dihydroisoquinolinone; or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.
9 . The compound of claim 1 having the structure of formula Ia
wherein
R 8 and R 9 are each independently H, halogen, CN, CONR 10 R 11 , OR 12 , CO 2 R 12 , COR 12 , or an alkyl, haloalkyl or cycloalkyl group each group optionally substituted;
R 10 and R 11 are each independently H or an alkyl, haloalkyl, cycloalkyl, aryl or heteroaryl group each group optionally substituted or R 10 and R 11 may be taken together with the atom to which they are attached to form an optionally substituted 4- to 7-membered ring optionally containing one or two additional heteroatoms selected from N, O or S; and
R 12 is H or an alkyl, haloalkyl, cycloalkyl, alkenyl, alkynyl, aryl or heteroaryl group each group optionally substituted; or
a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.
10 . The compound of claim 9 wherein R 8 is H or halogen, and R 9 is CONR 10 R 11 ; or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.
11 . The compound of claim 1 wherein m is 0 or 1; or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.
12 . The compound of claim 1 wherein n is 2 or 3; or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.
13 . The compound of claim 1 wherein q is 1 or 2; or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.
14 . The compound of claim 1 selected from the group consisting of:
6-(4-fluorophenyl)-2-(2-pyrrolidin-1-ylethyl)-3,4-dihydroisoquinolin-1(2H)-one;
6-(3,5-difluorophenyl)-2-(2-pyrrolidin-1-ylethyl)-3,4-dihydroisoquinolin-1(2H)-one;
6-(2,4-difluorophenyl)-2-(2-pyrrolidin-1-ylethyl)-3,4-dihydroisoquinolin-1(2H)-one;
6-(2-fluorophenyl)-2-(2-pyrrolidin-1-ylethyl)-3,4-dihydroisoquinolin-1(2H)-one;
2-(2-pyrrolidin-1-ylethyl)-6-[3-(trifluoromethoxy)phenyl]-3,4-dihydroisoquinolin-1(2H)-one;
2-(2-pyrrolidin-1-ylethyl)-6-[4-(trifluoromethoxy)phenyl]-3,4-dihydroisoquinolin-1(2H)-one;
3-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzonitrile;
6-phenyl-2-(2-pyrrolidin-1-ylethyl)-3,4-dihydroisoquinolin-1(2H)-one;
6-(3,4-difluorophenyl)-2-(2-pyrrolidin-1-ylethyl)-3,4-dihydroisoquinolin-1(2H)-one;
6-(3-fluorophenyl)-2-(2-pyrrolidin-1-ylethyl)-3,4-dihydroisoquinolin-1(2H)-one;
4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzonitrile;
2-(2-pyrrolidin-1-ylethyl)-6-[3-(trifluoromethyl)phenyl]-3,4-dihydroisoquinolin-1(2H)-one;
6-(1,3-benzodioxol-5-yl)-2-(2-pyrrolidin-1-ylethyl)-3,4-dihydroisoquinolin-1(2H)-one;
2-(2-pyrrolidin-1-ylethyl)-6-[4-(trifluoromethyl)phenyl]-3,4-dihydroisoquinolin-1(2H)-one;
6-(4-methoxyphenyl)-2-(2-pyrrolidin-1-ylethyl)-3,4-dihydroisoquinolin-1(2H)-one;
methyl 4-(1-oxo-2-(2-(pyrrolidin-1-yl)ethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)benzoate;
methyl 4-(2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-1-oxo-1,2,3,4-tetrahydroiso-quinolin-6-yl)benzoate;
4-(2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)benzonitrile;
3-(2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-1-oxo-1,2,3,4-tetrahydroisoquinolin-5-yl)benzonitrile;
4-(2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-1-oxo-1,2,3,4-tetrahydroisoquinolin-5-yl)benzonitrile;
4-[1-oxo-2-(3-pyrrolidin-1-ylpropyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzonitrile;
3-[1-oxo-2-(3-pyrrolidin-1-ylpropyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzonitrile;
6-pyridin-4-yl-2-(2-pyrrolidin-1-ylethyl)-3,4-dihydroisoquinolin-1(2H)-one;
1-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]-1H-indole-5-carbonitrile;
6-(pyrrolidin-1-ylcarbonyl)-2-(2-pyrrolidin-1-ylethyl)-3,4-dihydroisoquinolin-1(2H)-one;
6-(4-fluorophenyl)-2-{2-[(2S)-2-methylpyrrolidin-1-yl]ethyl}-3,4-dihydroisoquinolin-1(2H)-one;
6-(4-fluorophenyl)-2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-3,4-dihydroisoquinolin-1(2H)-one;
4-(2-{2-[(2S)-2-methylpyrrolidin-1-yl]ethyl}-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)benzonitrile;
4-(2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)benzonitrile;
6-{[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]oxy}nicotinonitrile;
6-[(2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)oxy]nicotinonitrile;
4-[(2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)oxy]benzonitrile;
4-{[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]oxy}benzonitrile;
5-[(2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-1-oxo-1,2,3,4-tetrahydroisoquinolin-6yl)oxy]pyridine-2-carbonitrile;
5-{[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]oxy}pyridine-2-carbonitrile;
6-[4-(pyrrolidin-1-ylcarbonyl)phenyl]-2-(2-pyrrolidin-1-ylethyl)-3,4-dihydroisoquinolin-1(2H)-one;
N-cyclopentyl-4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzamide;
N,N-dimethyl-4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzamide;
N-cyclopropyl-4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzamide;
N-ethyl-4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzamide;
N-methyl-4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzamide;
N-(cyclopropylmethyl)-4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroiso-quinolin-6-yl]benzamide;
N-isopropyl-4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzamide;
N,N-diethyl-4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6yl]benzamide;
N-cyclobutyl-4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzamide;
6-[4-(azetidin-1-ylcarbonyl)phenyl]-2-(2-pyrrolidin-1-ylethyl)-3,4-dihydroisoquinolin-1(2H)-one;
N,N-diethyl-4-(2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)benzamide;
2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-6-[4-(pyrrolidin-1-ylcarbonyl)phenyl]-3,4-dihydroisoquinolin-1(2H)-one;
4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzamide;
N-(2-fluoroethyl)-4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzamide;
N-(2-methoxyethyl)-4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzamide;
N-(2-isopropoxyethyl)-4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzamide;
4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]-N-(2-phenoxyethyl)benzamide;
N-(2-ethoxyethyl)-4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzamide;
N-(cyclopropylmethyl)-4-(2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)benzamide;
N-cyclobutyl-4-(2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)benzamide;
N-ethyl-4-(2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)benzamide;
N-cyclopropyl-4-(2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)benzamide;
N-isopropyl-4-(2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)benzamide;
N-methyl-4-(2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)benzamide;
6-[4-(piperidin-1-ylcarbonyl)phenyl]-2-(2-pyrrolidin-1-ylethyl)-3,4-dihydroisoquinolin-1(2H)-one;
N-cyclopentyl-4-(2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)benzamide;
6-(4-{[(2S)-2-methylpyrrolidin-1-yl]carbonyl}phenyl)-2-(2-pyrrolidin-1-ylethyl)-3,4,-dihydroisoquinolin-1(2H)-one;
6-(4-{[(2R)-2-methylpyrrolidin-1-yl]carbonyl}phenyl)-2-(2-pyrrolidin-1-ylethyl)-3,4-dihydroisoquinolin-1(2H)-one;
N-methyl-4-(2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-1-oxo-1,2,3,4-tetrahdyroiso-quinolin-7-yl)benzamide;
N-ethyl-4-(2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-1-oxo-1,2,3,4-tetrahydroiso-quinolin-7-yl)benzamide;
N-isopropyl-4-(2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-1-oxo-1,2,3,4-tetrahydroiso-quinolin-7-yl)benzamide;
2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-7-[4-(pyrrolidin-1-ylcarbonyl)phenyl]-3,4-dihydroisoquinolin-1(2H)-one;
4-{[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]oxy}benzamide
N-methyl-4-{[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]oxy}benzamide
N-ethyl-4-{[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]oxy}benzamide;
N-isopropyl-4-{[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]oxy}benzamide;
N,N-dimethyl-4-{[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]oxy}benzamide;
N,N-diethyl-4-{[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]oxy}benzamide;
N-cyclobutyl-4-{[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]oxy}benzamide;
6-[4-(pyrrolidin-1-ylcarbonyl)phenoxy]-2-(2-pyrrolidin-1-ylethyl)-3,4-dihydroiso-quinolin-1(2H)-one;
N-cyclopropyl-4-{[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]oxy}benzamide;
N-methyl-6-{[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]oxy}nicotinamide;
N-methoxy-N-methyl-4-(1-oxo-2-(2-(pyrrolidin-1-yl)ethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)benzamide;
6-[4-(cyclopropylcarbonyl)phenyl]-2-(2-pyrrolidin-1-ylethyl)-3,4-dihydroisoquinolin-1(2H)-one;
6-(1H-benzimidazol-1-yl)-2-(2-pyrrolidin-1-ylethyl)-3,4-dihydroisoquinolin-1(2H)-one;
5-(1H-benzimidazol-1-ylmethyl)-2-(2-pyrrolidin-1-ylethyl)isoindolin-1-one;
6-(4-fluorophenyl)-2-(2-piperidin-1-ylethyl)-3,4-dihydroiso-quinolin-1(2H-one;
4-[1-oxo-2-(3-piperidin-1-ylpropyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzonitrile;
2-(2-azepan-1-ylethyl)-6-(4-fluorophenyl)-3,4-dihydroisoquinolin-1(2H)-one;
4-{[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]oxy}benzamide;
4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzoic acid;
4-{[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]oxy}benzoic acid;
(R)-4-(2-(2-(2-methylpyrrolidin-1-yl)ethyl)-1-oxoisoindolin-5-yl)benzonitrile;
4-{[(2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)oxy]methyl}benzonitrile;
4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]-N-(2-thienylmethyl)benzamide;
6-[4-(morpholin-4-ylcarbonyl)phenyl]-2-(2-pyrrolidin-1-ylethyl)-3,4-dihydroisoquinolin-1(2H)-one;
N-(2-chloroethyl)-4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzamide;
N-ethyl-N-methyl-4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzamide;
N-(2-furylmethyl)-4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzamide;
N-[(1 S)-2-methoxy-1-methylethyl]-4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzamide;
6-{4-[(3-methoxypyrrolidin-1-yl)carbonyl]phenyl}-2-(2-pyrrolidin-1-ylethyl)-3,4-dihydroisoquinolin-1(2H)-one;
6-(4-{[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]carbonyl}phenyl)-2-(2-pyrrolidin-1-ylethyl)-3,4-dihydroisoquinolin-1(2H)-one;
4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]-N-propylbenzamide;
4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]-N-1,3-thiazol-2-ylbenzamide;
6-[4-fluoro-3-(pyrrolidin-1-ylcarbonyl)phenyl]-2-(2-pyrrolidin-1-ylethyl)-3,4-dihydroisoquinolin-1(2H)-one;
2-fluoro-N,N-dimethyl-5-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzamide;
3-fluoro-N,N-dimethyl-4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzamide;
6-[2-fluoro-4-(pyrrolidin-1-ylcarbonyl)phenyl]-2-(2-pyrrolidin-1-ylethyl)-3,4-dihydroisoquinolin-1(2H)-one;
6-[3-fluoro-4-(pyrrolidin-1-ylcarbonyl)phenyl]-2-(2-pyrrolidin-1-ylethyl)-3,4-dihydroisoquinolin-1(2H)-one;
6-[3-chloro-4-(pyrrolidin-1-ylcarbonyl)phenyl]-2-(2-pyrrolidin-1-ylethyl)-3,4-dihydroisoquinolin-1(2H)-one;
2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-6-[4-(pyrrolidin-1-ylcarbonyl)phenoxy]-3,4-dihydroisoquinolin-1(2H)-one;
N-ethyl-4-[2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzamide;
N-methyl-4-[2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzamide;
6-[4-(pyrrolidin-1-ylcarbonyl)phenyl]-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinoline;
N,N-dimethyl-4-[2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzamide;
6-[4-(piperidin-1-ylcarbonyl)phenyl]-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinoline;
6-[4-(morpholin-4-ylcarbonyl)phenyl]-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinoline;
4-[2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzamide;
N-methyl-4-[1-oxo-2-(3-pyrrolidin-1-ylpropyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzamide;
6-(4-{[(2S)-2-methylpyrrolidin-1-yl]carbonyl}phenyl)-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinoline;
6-(1H-pyrazol-1-yl)-2-(2-pyrrolidin-1-ylethyl)-3,4-dihydroisoquinolin-1(2H)-one;
6-(1H-indazol-1-yl)-2-(2-pyrrolidin-1-ylethyl)-3,4-dihydroisoquinolin-1(2H)-one;
2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-3,3′,4,4′-tetrahydro-6,6′-biisoquinoline-1,1′(2H,2′H)-dione;
6-(azepan-1-ylcarbonyl)-2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-3,4-dihydroiso-quinolin-1(2H)-one;
N-cyclobutyl-2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-1-oxo-1,2,3,4-tetrahydroiso-quinoline-6-carboxamide;
2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-6-(piperidin-1-ylcarbonyl)-3,4-dihydro-isoquinolin-1(2H)-one;
N-cyclohexyl-2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-1-oxo-1,2,3,4-tetrahydroiso-quinoline-6-carboxamide;
N-(2,3-dihydro-1H-inden-2-yl)-2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-1-oxo-1,2,3,4-tetrahydroisoquinoline-6-carboxamide;
2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-1-oxo-N-pyridin-4-yl-1,2,3,4-tetrahydroisoqui-noline-6-carboxamide;
N-cyclopentyl-2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-1-oxo-1,2,3,4-tetrahydroiso-quinoline-6-carboxamide;
6-(3,4-dihydroisoquinolin-2(1H)-ylcarbonyl)-2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-3,4-dihydroisoquinolin-1(2H)-one;
2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-6-(pyrrolidin-1-ylcarbonyl)-3,4-dihydroiso-quinolin-1(2H)-one;
6-(1,3-dihydro-2H-isoindol-2-ylcarbonyl)-2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-dihydroisoquinolin-1(2H)-one;
6-(4-fluorophenyl)-2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-1,2,3,4-tetrahydroiso-quinoline;
2-(2-pyrrolidin-1-ylethyl)-6-[4-(trifluoromethoxy)phenyl]-1,2,3,4-tetrahydroisoquinoline;
6-(3-fluorophenyl)-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinoline;
6-(1,3-benzodioxol-5-yl)-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinoline;
6-(4-fluorophenyl)-2-(2-piperidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinoline;
2-(2-azepan-1-ylethyl)-6-(4-fluorophenyl)-1,2,3,4-tetrahydroisoquinoline;
3-fluoro-N-methyl-4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzamide;
N-ethyl-3-fluoro-4-[1-oxo-2-(2-pyrrolidin-1-ylethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]benzamide;
6-(1H-benzimidazol-1-yl)-2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-3,4-dihydroiso-quinolin-1(2H)-one;
2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-5-[4-(pyrrolidin-1-ylcarbonyl)phenyl]-isoindolin-1-one;
N-methyl-4-(2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-1-oxo-2,3-dihydro-1H-isoindol-5-yl)benzamide;
6-[4-(methylsulfonyl)phenyl]-2-(2-pyrrolidin-1-ylethyl)-3,4-dihydroisoquinolin-1(2H)-one;
2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-6-piperidin-1-yl-3,4-dihydroisoquinolin-1(2H)-one;
6-(piperidin-1-yl)-2-(2-(pyrrolidin-1-yl)ethyl)-3,4-dihydroisoquinolin-1(2H)-one;
6-(piperidin-1-yl)-2-(2-(piperidin-1-yl)ethyl)-3,4-dihydroisoquinolin-1(2H)-one;
2-(2-(azepan-1-yl)ethyl)-6-(piperidin-1-yl)-3,4-dihydroisoquinolin-1(2H)-one;
(R)-2-(2-(2-methylpyrrolidin-1-yl)ethyl)-6-(pyrrolidin-1-yl)-3,4-dihydroisoquinolin-1(2H)-one;
(R)-6-(azepan-1-yl)-2-(2-(2-methylpyrrolidin-1-yl)ethyl)-3,4-dihydroisoquinolin-1(2H)-one;
(R)-2-methyl-2′-(2-(2-methylpyrrolidin-1-yl)ethyl)-3,3′,4,4′-tetrahydro-6,6′-biisoqui-noline-1,1′(2H,2′H)-dione;
2-methyl-2′-(2-(pyrrolidin-1-yl)ethyl)-3,3′,4,4′-tetrahydro-6,6′-biisoquinoline-1,1′(2H,2′H)-dione;
2-(3-(pyrrolidin-1-yl)propyl)-6-(4-(pyrrolidine-1-carbonyl)phenyl)-3,4-dihydroiso-quinolin-1(2H)-one;
6-(isoindoline-2-carbonyl)-2-(2-(pyrrolidin-1-yl)ethyl)-3,4-dihydroisoquinolin-1(2H)-one;
6-(piperidine-1-carbonyl)-2-(2-(pyrrolidin-1-yl)ethyl)-3,4-dihydroisoquinolin-1(2H)-one;
(R)-N,N-dimethyl-4-(2-(2-(2-methylpyrrolidin-1-yl)ethyl)-1-oxo-1,2,3,4-tetrahydroiso-quinolin-6-yl)benzamide;
(R)-6-(4-(azetidine-1-carbonyl)phenyl)-2-(2-(2-methylpyrrolidin-1-yl)ethyl)-3,4-dihydroisoquinolin-1(2H)-one;
(R)-2-(2-(2-methylpyrrolidin-1-yl)ethyl)-6-(4-(piperidine-1-carbonyl)phenyl)-3,4-dihydroisoquinolin-1(2H)-one;
(R)-2-(2-(2-methylpyrrolidin-1-yl)ethyl)-6-(4-(morpholine-4-carbonyl)phenyl)-3,4-dihydroisoquinolin-1(2H)-one;
(R)-N-(2-methoxyethyl)-4-(2-(2-(2-methylpyrrolidin-1-yl)ethyl)-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)benzamide;
(R)-N-(2-isopropoxyethyl)-4-(2-(2-(2-methylpyrrolidin-1-yl)ethyl)-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)benzamide;
N-((S)-1-methoxypropan-2-yl)-4-(2-(2-((R)-2-methylpyrrolidin-1-yl)ethyl)-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)benzamide;
(R)-N-(2-fluoroethyl)-4-(2-(2-(2-methylpyrrolidin-1-yl)ethyl)-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)benzamide;
6-(4-((S)-2-(methoxymethyl)pyrrolidine-1-carbonyl)phenyl)-2-(2-((R)-2-methylpyrrolidin-1-yl)ethyl)-3,4-dihydroisoquinolin-1(2H)-one; and
(R)-N-ethyl-N-methyl-4-(2-(2-(2-methylpyrrolidin-1-yl)ethyl)-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)benzamide; or
a tautomer or pharmaceutically acceptable salt thereof.
15 . A method for the treatment of a patient suffering from a cognitive disorder related to or affected by the Histamine-3 (H 3 ) receptor comprising admistering to the patient a compound of formula I
wherein
X 1 is (CR 4 R 5 ) p , CO or O;
X 2a and X 2b are each H or are taken together to form ═O;
m is 0, 1 or 2;
n is 2,3 or 4;
p is 0, 1 or 2;
q is 1, 2 or 3;
R 1 and R 2 are each independently H, halogen or an alkyl or haloalkyl group each group optionally substituted;
R 3 is NR 6 R 7 or an alkyl, cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each group optionally substituted with the proviso that when X 1 is O then R 3 must be other than NR 6 R 7 ;
R 4 and R 5 are each independently H or an optionally substituted alkyl or cycloalkyl group; and
R 6 and R 7 each independently H or an alkyl, alkenyl, alkoxy, cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each group optionally substituted or R 6 and R 7 may be taken together with the atom to which they are attached to form an optionally substituted 4- to 7-membered ring optionally containing one or two additional heteroatoms selected from N, O or S or an optionally substituted fused bicyclic or tricyclic 9- to 15-membered aromatic ring system optionally containing one to three additional heteroatoms selected from N, O or S; or
a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.
16 . The method of claim 15 , wherein said disorder is a neurodegenerative disorder.
17 . The method of claim 15 , wherein said disorder is mild cognitive impairment (MCl), dementia, delirium, amnestic disorder, Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), memory disorder, memory deficits associated with depression, schizophrenia, a psychotic disorder, paranoia, mano-depressive illness, attention deficit hyperactivity disorder (ADHD), dyslexia, developmental disorders, Down's syndrome, Fragile X syndrome, loss of executive function, loss of learned information, vascular dementia, cognitive decline, neurodegenerative disorder, HIV-induced dimentia, head trauma, Pick's disease, Creutzfeldt-Jakob disease, Body dementia, vascular dementia, surgical procedure-induced cognitive dysfunction, traumatic brain injury or stroke.
18 . The method of claim 15 , wherein said disorder is selected from the group consisting of: Alzheimer's disease, attention deficit disorder, schizophrenia, cognitive dysfunction in schizophrenia, Parkinsons' disease, frontal temporal dementia or depression.
19 . A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound according to claim 1 .
20 . A process for the preparation of a compound of formula I
wherein
X 1 is (CR 4 R 5 ) p , CO or O;
X 2a and X 2b are each H or are taken together to form ═O;
m is 0, 1 or 2;
n is 2, 3 or 4;
p is 0, 1 or 2;
q is 1, 2 or 3;
R 1 and R 2 are each independently H, halogen or an alkyl or haloalkyl group each group optionally substituted;
R 3 is NR 6 R 7 or an alkyl, cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each group optionally substituted with the proviso that when X 1 is O then R 3 must be other than NR 6 R 7 ;
R 4 and R 5 are each independently H or an optionally substituted alkyl or cycloalkyl group; and
R 6 and R 7 each independently H or an alkyl, alkenyl, alkoxy, cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each group optionally substituted or R 6 and R 7 may be taken together with the atom to which they are attached to form an optionally substituted 4- to 7-membered ring optionally containing one or two additional heteroatoms selected from N, O or S or an optionally substituted fused bicyclic or tricyclic 9- to 15-membered aromatic ring system optionally containing one to three additional heteroatoms selected from N, O or S; or
a stereoisomer, tautomer or pharmaceutically acceptable salt thereof
which process comprises reacting a compound of formula II
wherein X 1 , X 2 , R 3 , m and n are as described hereinabove for formula I with a pyrrolidine of formula III
wherein R 1 and R 2 are as described hereinabove for formula I in the presence of a NaBH 3 CN optionally in the presence of an acid optionally in the presence of a solvent.